Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Chi Sheng Pharma & Biotech Co's annualizedNet Income for the quarter that ended in Dec. 2025 was NT$183 Mil.
Chi Sheng Pharma & Biotech Co's average Total Assets over the quarter that ended in Dec. 2025 was NT$1,922 Mil. Therefore, Chi Sheng Pharma & Biotech Co's annualized ROA % for the quarter that ended in Dec. 2025 was 9.50%.
The historical rank and industry rank for Chi Sheng Pharma & Biotech Co's ROA % or its related term are showing as below:
ROCO:4111'
s ROA % Range Over the Past 10 Years
Min: 2.83 Med: 5.09 Max: 8.91
Current: 8.91
During the past 13 years, Chi Sheng Pharma & Biotech Co's highest ROA % was 8.91%. The lowest was 2.83%. And the median was 5.09%.
ROCO:4111's ROA % is ranked better than 84.23% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 0.555
vs ROCO:4111: 8.91
Chi Sheng Pharma & Biotech Co (ROCO:4111) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Chi Sheng Pharma & Biotech Co ROA % Related Terms
Chi Sheng Pharma & Biotech Co ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Chi Sheng Pharma & Biotech Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chi Sheng Pharma & Biotech Co ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Chi Sheng Pharma & Biotech Co's ROA % distribution charts can be found below:
* The bar in red indicates where Chi Sheng Pharma & Biotech Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Chi Sheng Pharma & Biotech Co (ROCO:4111) has a ROA % of 9.50% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Chi Sheng Pharma & Biotech Co and its competitors. This is 87% above median its historical median of 5.09. Over the past decade, Chi Sheng Pharma & Biotech Co's ROA % has ranged from 2.83 to 8.91. According to the industry distribution chart, Chi Sheng Pharma & Biotech Co ranks #135 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 15.8%.
Is Chi Sheng Pharma & Biotech Co's ROA % too high?
Chi Sheng Pharma & Biotech Co's current ROA % of 9.50% is 87% above median its 10-year median of 5.09. Over the past 10 years, this metric has ranged from a low of 2.83 to a high of 8.91. The Medical Devices & Instruments industry median ROA % is 0.56. Chi Sheng Pharma & Biotech Co's value of 9.50% is 1611.7% above this industry median. Based on the distribution chart, Chi Sheng Pharma & Biotech Co ranks #135 out of 856 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Chi Sheng Pharma & Biotech Co has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chi Sheng Pharma & Biotech Co's ROA % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Chi Sheng Pharma & Biotech Co ranks #135 out of 856 companies for ROA %. This places Chi Sheng Pharma & Biotech Co in the top 16% of its industry — outperforming the majority of peers. The industry median ROA % is 0.56. Chi Sheng Pharma & Biotech Co's value of 9.50% is 1611.7% above this benchmark. Historically, Chi Sheng Pharma & Biotech Co's own ROA % has ranged from 2.83 to 8.91 over the past decade. While the company's 10-year median is 5.09 vs. the industry median of 0.56, Chi Sheng Pharma & Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.56, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chi Sheng Pharma & Biotech Co's current ROA % of 9.50% is 1611.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Chi Sheng Pharma & Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chi Sheng Pharma & Biotech Co's current ROA % is 9.50%, which is 87% above median its own 10-year median of 5.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chi Sheng Pharma & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co (ROCO:4111) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.14, compared to a current price of NT$30.05 — trading 9.3% below its estimated fair value. The current ROA % is 9.50%, which is 87% above median its 10-year median of 5.09 and 1611.7% above the Medical Devices & Instruments industry median of 0.56. Chi Sheng Pharma & Biotech Co's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Chi Sheng Pharma & Biotech Co (ROCO:4111), the current ROA % is 9.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chi Sheng Pharma & Biotech Co (ROCO:4111) Overvalued in 2026?
Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co stock appears to be undervalued.
The current stock price of NT$30.05 is trading 9.3% below its estimated GF Value™ of NT$33.14.
GuruFocus considers Chi Sheng Pharma & Biotech Co to be Fairly Valued.
Key valuation signals for ROCO:4111:
ROA %: 9.50% (87% above median its 10-year median of 5.09)
GF Value™: NT$33.14 vs. price of NT$30.05 (9.3% below fair value)
Industry Position: 1611.7% above the Medical Devices & Instruments median (#135 of 856)
No single metric tells the full story. See the ROCO:4111 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chi Sheng Pharma & Biotech Co Business Description
Chi Sheng Pharma & Biotech Co Ltd manufactures and distributes medical medicines and equipment in Taiwan. It offers injections, including hemodialysis solutions, amino acid injections, vitamin injections, and externally applied medicines.
84GF Score
Get the complete analysis for ROCO:4111
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4111 has been successfully added to your 
